Impact of pharmacist care in the management of cardiovascular disease risk factors: A systematic review and meta-analysis of randomized trials

Archives of Internal Medicine

Volumn 171, Issue 16, 2011, Pages 1441-1453

  Santschi, Valérie ^a,b   Chiolero, Arnaud ^a,b   Burnand, Bernard ^b   Colosimo, April L ^a   Paradis, Gilles ^a,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BLOOD PRESSURE FLUCTUATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CINAHL; COCHRANE LIBRARY; DIASTOLIC BLOOD PRESSURE; DRUG MONITORING; EMBASE; FEEDBACK SYSTEM; HUMAN; MEDICAL EDUCATION; MEDLINE; NURSE; OUTPATIENT; PATIENT EDUCATION; PHARMACIST; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMINDER SYSTEM; REVIEW; SMOKING; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; PATIENT EDUCATION AS TOPIC; PHARMACISTS; PROFESSIONAL-PATIENT RELATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SMOKING; TREATMENT OUTCOME;

EID: 80052732493     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.399     Document Type: Review

References (55)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747-1757.
2. Heart and Stroke Foundation of Canada. The changing face of heart disease and stroke in Canada 2000. Ottawa, Canada: Laboratory Centre for Disease Control, Health Canada, Statistics Canada, Canada Institute for Health Information, Canadian Cardiovascular Society, Canadian Stroke Society, Heart Stroke Foundation of Canada; 1999. http://dsp-psd.pwgsc.gc.ca/Collection/H88-3- 30-2001/pdfs/age/face-e.pdf. Accessed July 11, 2011.
3. Lloyd-Jones D, Adams RJ, Brown TM, et al; Writing Group Members; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.
4. Forrester JS, Merz CN, Bush TL, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events: Task Force 4: efficacy of risk factor management. J Am Coll Cardiol. 1996;27(5):991-1006.
5. Bhatt DL, Steg PG, Ohman EM, et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-189. (Pubitemid 43076437)
6. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10-17. (Pubitemid 38031904)
7. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multi-center survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459-467.
8. Dobson RT, Taylor JG, Henry CJ, et al. Taking the lead: community pharmacists' perception of theirrole potential within the primary care team. Res Social Adm Pharm. 2009;5(4):327-336.
9. Bogden PE, Koontz LM, Williamson P, Abbott RD. The physician and pharmacist team: an effective approach to cholesterol reduction. J Gen Intern Med. 1997;12(3):158-164. (Pubitemid 27180568)
10. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med. 2002;162(10):1149-1155. (Pubitemid 34522403)
11. Murray MD, Ritchey ME, Wu J, Tu W. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease. Arch Intern Med. 2009;169(8):757-763.
12. Gardner SF, Skelton DR, Rollins SD, Hastings JK. Community pharmacy data bases to identify patients at high risk for hypercholesterolemia. Pharmacotherapy. 1995;15(3):292-296.
13. Koren MJ, Hunninghake DB; ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004;44(9):1772-1779. (Pubitemid 39424074)
14. Olson KL, Rasmussen J, Sandhoff BG, Merenich JA; Clinical Pharmacy Cardiac Risk Service Study Group. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med. 2005;165(1):49-54. (Pubitemid 40096081)
15. Pearson GJ, Olson KL, Panich NE, et al. Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience. Vasc Health Risk Manag. 2008;4(5):1127-1135.
16. Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med. 2005;118(3):276-284. (Pubitemid 40312639)
17. Taveira TH, Wu WC, Martin OJ, Schleinitz MD, Friedmann P, Sharma SC. Pharmacist-led cardiac risk reduction model. Prev Cardiol. 2006;9(4):202-208.
18. Carter BL, Bergus GR, Dawson JD, et al. A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Greenwich). 2008;10(4):260-271.
19. McLean DL, McAlister FA, Johnson JA, et al; SCRIPHTN Investigators. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med. 2008;168(21):2355-2361.
20. Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999;159(16):1939-1945. (Pubitemid 29424715)
21. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med. 2008;168(7):687-694. (Pubitemid 351563951)
22. McConnell KJ, Denham AM, Olson KL. Pharmacistled interventions for the management of cardiovascular disease - opportunities and obstacles. Dis Manag Health Outcomes. 2008;16(3):131-144. (Pubitemid 351744852)
23. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, West Sussex; Hoboken NJ: Wiley-Blackwell; 2008.
24. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
25. Hennessy S, Leonard CE, Yang W, et al. Effectiveness of a two-part educational intervention to improve hypertension control: a cluster-randomized trial. Pharmacotherapy. 2006;26(9):1342-1347. (Pubitemid 44306894)
26. Chiu CC, Wu SS, Lee PY, Huang YC, Tan TY, Chang KC. Control of modifiable risk factors in ischemic stroke outpatients by pharmacist intervention: an equal allocation stratified randomized study. J Clin Pharm Ther. 2008;33(5):529-535.
27. Dent LA, Harris KJ, Noonan CW. Randomized trial assessing the effectiveness of a pharmacist-delivered program for smoking cessation. Ann Pharmacother. 2009;43(2):194-201.
28. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study: Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000;20(12):1508-1516.
29. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy. 2000;20(4):410-416. (Pubitemid 30198847)
30. Garção JA, Cabrita J. Evaluation of a pharmaceutical care program for hypertensive patients in rural Portugal. J Am Pharm Assoc (Wash). 2002;42(6):858-864.
31. Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA. 2008;299(24):2857-2867. (Pubitemid 351930885)
32. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563-2571. (Pubitemid 44903860)
33. McKenney JM, Slining JM, Henderson HR, Devins D, Barr M. The effect of clinical pharmacy services on patients with essential hypertension. Circulation. 1973;48(5):1104-1111.
34. Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with un-controlled hypertension. Pharmacotherapy. 2000;20(11):1384-1389.
35. McMillan Nola K, Gourley DR, Portner TS, et al. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc (Wash). 2000;40(2):166-173.
36. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy. 2001;21(11):1337-1344.
37. Paulós CP, Nygren CE, Celedón C, Cárcamo CA. Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia. Ann Pharmacother. 2005;39(5):939-943. (Pubitemid 40570674)
38. Peterson GM, Fitzmaurice KD, Naunton M, Vial JH, Stewart K, Krum H. Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy. J Clin Pharm Ther. 2004;29(1):23-30. (Pubitemid 38253533)
39. Sookaneknun P, Richards RM, Sanguansermsri J, Teerasut C. Pharmacist involvement in primary care improves hypertensive patient clinical outcomes. Ann Pharmacother. 2004;38(12):2023-2028. (Pubitemid 40169369)
40. Vial RJ, Jones TE, Ruffin RE, Gilbert AL. Smoking cessation program using nicotine patches linking hospital to the community. J Pharm Pract Res. 2002;32(1):57-62. (Pubitemid 35416158)
41. Villa LA, Von Chrismar AM, Oyarzun C, Eujenin P, Fernandez ME, Quezada M. Pharmaceutical Care Program for dyslipidemic patients at three primary health care centers: impacts and outcomes. Latin Am J Pharm. 2009;28(3):415-420.
42. Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy. 2002;22(12):1533-1540. (Pubitemid 35429949)
43. Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). J Gen Intern Med. 2005;20(12):1091-1096. (Pubitemid 43110257)
44. Bogden PE, Abbott RD, Williamson P, Onopa JK, Koontz LM. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. J Gen Intern Med. 1998;13(11):740-745. (Pubitemid 28523563)
45. Borenstein JE, Graber G, Saltiel E, et al. Physician-pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy. 2003;23(2):209-216. (Pubitemid 36204018)
46. Carter BL, Ardery G, Dawson JD, et al. Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med. 2009;169(21):1996-2002.
47. de Castro MS, Fuchs FD, Santos MC, et al. Pharmaceutical care program for patients with uncontrolled hypertension: report of a double-blind clinical trial with ambulatory blood pressure monitoring. Am J Hypertens. 2006;19(5):528-533.
48. Hunt JS, Siemienczuk J, Pape G, et al. A randomized controlled trial of team-based care: impact of physician-pharmacist collaboration on uncontrolled hypertension. J Gen Intern Med. 2008;23(12):1966-1972.
49. Lee VW, Fan CS, Li AW, Chau AC. Clinical impact of a pharmacist-physician co-managed programme on hyperlipidaemia management in Hong Kong. J Clin Pharm Ther. 2009;34(4):407-414.
50. Santschi V, Rodondi N, Bugnon O, Burnier M. Impact of electronic monitoring of drug adherence on blood pressure control in primary care: a cluster 12-month randomised controlled study. Eur J Intern Med. 2008;19(6):427-434.
51. Solomon DK, Portner TS, Bass GE, et al. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc (Wash). 1998;38(5):574-585.
52. Villeneuve J, Genest J, Blais L, et al. A cluster randomized controlled trial to evaluate an ambulatory primary care management program for patients with dyslipidemia: the TEAM study. CMAJ. 2010;182(5):447-455.
53. Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48(10):923-933.
54. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.
55. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ. 1994;309(6965):1351-1355 (Pubitemid 24345976)